Share: Share on Facebook Share on Twitter Share on LinkedIn I recommend visiting to read:%0A%0A {0} %0A%0A {1}
Life Sciences Golden Triangle Report Life Sciences Golden Triangle Report

Life Sciences: Golden Triangle Report

Jamie Renison • 01/08/2023

Our latest Life Sciences Lab Report on the UK's Golden Triangle. The report looks closely at investment volumes, leasing take up, lab supply and pipeline, and investment into life sciences real estate across Cambridge, Oxford and London.

Strong active demand requirements persisted in the life sciences occupational market across the Golden Triangle in Q2 2023 despite take-up decreasing on the quarter.

This decrease in the volume exchanged was attributed to the supply shortage of good quality stock, while pressure on early stage VC-backed companies to cut costs also impacted transaction levels.

Real estate investment activity was down in Q2, with the successive interest rate rises challenging viability models and weighing on pricing.

The underlying strength in the growing sector and the volume of requirements in the market paint a positive picture ahead for activity and rental growth – provided the stock necessary to fuel growth is brought forward – while the investment market is looking for stability and eventual easing in the base rate to bring renewed momentum to activity levels.

Key Takeaways:

  • Golden Triangle investment volumes reached £381 million in Q2 2023;
  • Leasing take-up in the Golden Triangle for the second quarter reached 59,300 sq ft;
  • Cambridge accounted for 74% of space transacted in Q2 at 44,000 sq ft;
  • Transaction volumes in all three markets were heavily restrained by the shortage of supply;
  • Early stage VC-backed companies were under increased pressure to cut costs, also impacting transaction levels;
  • Active requirements in the market equate to 34% of the total existing stock;
  • There is 1.8 million sq ft of life sciences space under construction;
  • A further 5.4 million sq ft has planning consent;
  • Venture capital investment in Golden Triangle life sciences companies totalled £344.2 million in Q2.


GSK Completes Sale Of Strategic Life Sciences Development Site

Real estate services firm Cushman & Wakefield has advised GSK plc on the sale of the surplus development land that sits alongside its 1 million sq ft Research & Development (R&D) facility in Stevenage to UBS Asset Management and Reef Group. 


Life Science

Life Sciences Update: October 2022

Following extraordinary investment, expansion, and innovation in 2021, the life sciences industry is poised for further growth and consistent demand in the years ahead.
Sandy Romero • 26/10/2022
Life Sciences Real Estate Services
We help life science companies create flexible real estate strategies to attract and retain top talent, while managing efficiency and costs.
Learn More

Ready to talk?

Get in touch with one of our professionals.
With your permission we and our partners would like to use cookies in order to access and record information and process personal data, such as unique identifiers and standard information sent by a device to ensure our website performs as expected, to develop and improve our products, and for advertising and insight purposes.

Alternatively click on More Options and select your preferences before providing or refusing consent. Some processing of your personal data may not require your consent, but you have a right to object to such processing.

You can change your preferences at any time by returning to this site or clicking on Cookies.
Agree and Close
These cookies ensure that our website performs as expected,for example website traffic load is balanced across our servers to prevent our website from crashing during particularly high usage.
These cookies allow our website to remember choices you make (such as your user name, language or the region you are in) and provide enhanced features. These cookies do not gather any information about you that could be used for advertising or remember where you have been on the internet.
These cookies allow us to work with our marketing partners to understand which ads or links you have clicked on before arriving on our website or to help us make our advertising more relevant to you.
Agree All
Reject All